Psychedelic-Assisted Therapy: Redefining the Treatment of Generalized Anxiety Disorder
Overview
This paper examines the results of a Phase 2b clinical trial demonstrating that MM120, an LSD derivative, produces rapid and sustained symptom improvement in patients with generalized anxiety disorder. The paper contrasts the neuroplasticity-based mechanisms of psychedelic-assisted therapy with traditional neurochemical imbalance models, arguing for a paradigm shift in psychiatric treatment approaches.
What this research paper covers
- Introduction and clinical trial overview of MM120 efficacy in GAD treatment
- Biological mechanisms including 5-HT2A receptor agonism and neuroplasticity pathways
- Comparison with conventional SSRI treatments and default-mode network disruption
- Theoretical implications challenging neurochemical imbalance theory
Preview
The Psychedelic-Assisted Therapy: Redefining the treatment of Generalized Anxiety Disorder.
Name
Institution
Course No
Professor
Date
On October 27, 2025, scientists in the University of California, San Francisco announced the first results of a randomized, controlled, and placebo-blinded Phase 2b trial indicating that a single oral dose of MM120, an investigational derivative of the lysergide (LSD) compound led to rapid, clinically significant and sustained symptom improvement in patients with generalized anxiety disorder (GAD) with a duration of at least twelve weeks (Mitchell et al., 2025). The trial under discussion took place under the guidance of neuroscientist Jennifer Mitchell; the participants included those with both moderate and severe GAD; the patients were those whose symptoms were not responding to conventional pharmacotherapy and psychotherapy. The subjects participating in the experiment administered a dose of MM120 (100200 ug), and the themed integration sessions were to take place to integrate the experiences of the participants psychologically. The magnitude and speed of reaction were much larger than that generally encountered using selective serotonin reuptake inhibitors (SSRI), which are the first line drug treatment but still require taking every day and can require the development of partial remission weeks of therapy (Strawn et al., 2022).
As to biological psychology, MM120 is a potent agonist of the serotonin 5 - Ht 2A receptor subtype of cortical pyramidal neurons. The intracellular responses that occur and are triggered by stimulating these receptors include increased release of glutamate and brain-derived neurotrophic factor (BDNF) and the mammalian target of rapamycin (mTOR) signaling pathway (Ly et al., 2023).